Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Egle

Showing results (1-10 of 83) with videos related to

Pageof 9
Sort By:
Drugs|January 17, 2025
Efficacy and Safety of CDK4/6 Inhibitors: A Focus on HR+/HER2- Early Breast CancerEva Valentina Klocker, Daniel Egle, Rupert Bartsch, et al.
Gynecologic Oncology|July 26, 2008
Validation of intraoperative risk assessment on frozen section for surgical management of endometrial carcinomaDaniel Egle, Barbara Grissemann, Alain G Zeimet, et al.
Biomolecules|February 25, 2023
Quantitative Proteomic Characterization of Foreign Body Response towards Silicone Breast Implants Identifies Chronological Disease-Relevant Biomarker DynamicsInes Schoberleitner, Klaus Faserl, Bettina Sarg, et al.
Cancers|August 14, 2025
Integrating Polygenic Scores into Multifactorial Breast Cancer Risk Assessment: Insights from the First Year of Clinical Implementation in Western AustriaLukas Forer, Gunda Schwaninger, Kathrin Taxer, et al.
Gynecologic Oncology|April 25, 2012
HE4 is an independent prognostic marker in endometrial cancer patientsIrene Mutz-Dehbalaie, Daniel Egle, Siegfried Fessler, et al.
Breast (Edinburgh, Scotland)|December 6, 2007
Disseminated tumor cells: are they ready for clinical use?Stephan Braun, Florian D Vogl, Alois Schneitter, et al.
Gynecologic Oncology|March 23, 2007
Modulation of CA-125 tumor marker shedding in ovarian cancer cells by erlotinib or cetuximabChristian Marth, Daniel Egle, Doris Auer, et al.
Wiener Klinische Wochenschrift|September 8, 2023
Updated Austrian treatment algorithm for metastatic triple-negative breast cancerRupert Bartsch, Gabriel Rinnerthaler, Edgar Petru, et al.
Diagnostics (Basel, Switzerland)|June 28, 2023
Peritumoural Strain Elastography of Newly Diagnosed Breast Tumours: Does Maximum Peritumoural Halo Depth Correlate with Tumour Differentiation and Grade?Leonhard Gruber, Johannes Deeg, Daniel Egle, et al.
Journal of Clinical Medicine|February 25, 2023
Is It All about Surface Topography? An Intra-Individual Clinical Outcome Analysis of Two Different Implant Surfaces in Breast ReconstructionInes Schoberleitner, Angela Augustin, Daniel Egle, et al.
Pageof 9

Showing results (1-10 of 83) with videos related to

Sort By:
Pageof 9
Drugs|January 17, 2025
Efficacy and Safety of CDK4/6 Inhibitors: A Focus on HR+/HER2- Early Breast CancerEva Valentina Klocker, Daniel Egle, Rupert Bartsch, et al.
Gynecologic Oncology|July 26, 2008
Validation of intraoperative risk assessment on frozen section for surgical management of endometrial carcinomaDaniel Egle, Barbara Grissemann, Alain G Zeimet, et al.
Biomolecules|February 25, 2023
Quantitative Proteomic Characterization of Foreign Body Response towards Silicone Breast Implants Identifies Chronological Disease-Relevant Biomarker DynamicsInes Schoberleitner, Klaus Faserl, Bettina Sarg, et al.
Cancers|August 14, 2025
Integrating Polygenic Scores into Multifactorial Breast Cancer Risk Assessment: Insights from the First Year of Clinical Implementation in Western AustriaLukas Forer, Gunda Schwaninger, Kathrin Taxer, et al.
Gynecologic Oncology|April 25, 2012
HE4 is an independent prognostic marker in endometrial cancer patientsIrene Mutz-Dehbalaie, Daniel Egle, Siegfried Fessler, et al.
Breast (Edinburgh, Scotland)|December 6, 2007
Disseminated tumor cells: are they ready for clinical use?Stephan Braun, Florian D Vogl, Alois Schneitter, et al.
Gynecologic Oncology|March 23, 2007
Modulation of CA-125 tumor marker shedding in ovarian cancer cells by erlotinib or cetuximabChristian Marth, Daniel Egle, Doris Auer, et al.
Wiener Klinische Wochenschrift|September 8, 2023
Updated Austrian treatment algorithm for metastatic triple-negative breast cancerRupert Bartsch, Gabriel Rinnerthaler, Edgar Petru, et al.
Diagnostics (Basel, Switzerland)|June 28, 2023
Peritumoural Strain Elastography of Newly Diagnosed Breast Tumours: Does Maximum Peritumoural Halo Depth Correlate with Tumour Differentiation and Grade?Leonhard Gruber, Johannes Deeg, Daniel Egle, et al.
Journal of Clinical Medicine|February 25, 2023
Is It All about Surface Topography? An Intra-Individual Clinical Outcome Analysis of Two Different Implant Surfaces in Breast ReconstructionInes Schoberleitner, Angela Augustin, Daniel Egle, et al.
Pageof 9